Picture loading failed.

Anti-ICOS therapeutic antibody (Pre-made Rozibafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Rozibafusp alfa (previously AMG 570) is being developed by Amgen and AstraZeneca, for the treatment of systemic lupus erythematosus (SLE) and rheumatoid.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-499-1mg 1mg Inquiry
GMP-Bios-ab-499-10mg 10mg Inquiry
GMP-Bios-ab-499-100mg 100mg Inquiry
GMP-Bios-ab-499-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ICOS therapeutic antibody (Pre-made Rozibafusp biosimilar,Whole mAb Fusion)
INN Name Rozibafusp
TargetICOS
FormatWhole mAb Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI Structure6x4t:BE:DF
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAmgen
Conditions Approvedna
Conditions ActiveSystemic lupus erythematosus
Conditions DiscontinuedRheumatoid arthritis
Development Techna